China Medical System Holdings Ltd.
↗Shenzhen, China
China Medical System Holdings Ltd. (CMS) is a leading platform-based specialty pharmaceutical company in China, focused on the R&D, manufacturing, and commercialization of innovative drugs. Originally established as a premier sales and marketing organization, CMS has successfully transitioned into an innovation-driven powerhouse with a robust pipeline of nearly 40 innovative candidates across dermatology, ophthalmology, cardio-cerebrovascular, and gastroenterology.
The company operates through a multi-platform strategy, including CMS R&D for global drug discovery, PharmaGend for manufacturing and CDMO services, and Rxilient Health, its Singapore-based hub for Southeast Asian market access. CMS is known for its aggressive licensing strategy, partnering with global firms like Incyte, Sun Pharma, and AstraZeneca to bring first-in-class and best-in-class therapies to the Chinese and broader Asian markets.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals & Biotechnology
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$1B-$5B
Founded:1995
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
Total Raised:$140M
Investors:BlackRock, The Vanguard Group, Fidelity
STOCK
Exchange:HKEX
Ticker:0867.HK
Market Cap:$4.2B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Small molecule, mAb, Bispecific Antibody, Topical Formulations
Active Trials:15
Trial Phases:Phase 1: 5 | Phase 2: 4 | Phase 3: 6
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:CMS Skinhealth, Rxilient Health, PharmaGend, Dermavon
Key Partnerships:Incyte (Povorcitinib and Ruxolitinib Cream), Insilico Medicine (AI Drug Discovery), Sun Pharma (Tildrakizumab), AstraZeneca (Plendil distribution)
COMPETITION
Position:Leader
Competitors:3SBio, Sino Biopharmaceutical, Jiangsu Hengrui Pharmaceuticals, Fosun Pharma
LEADERSHIP
Key Executives:
Lam Kong - Chairman & CEO
Chen Hongbing - Chief Operating Officer
Scientific Founders:Lam Kong
Board Members:Lam Kong, Chen Hongbing, Lai Weixin, Chen Yanling
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with China Medical System Holdings Ltd.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.